Earnings ·
ImmunityBio reported Q2 2026 net product revenue of $50.7 million, a 92% year-over-year increase and the eighth…
IBRXImmunityBio, Inc.
ImmunityBio reported Q2 2026 net product revenue of $50.7 million, a 92% year-over-year increase and the eighth consecutive quarter of sequential growth driven by ANKTIVA adoption. First-half revenue reached $94.8 million, up 121%. The company holds $357.4 million in cash and marketable securities as of June 30, 2026. Regulatory updates include a UAE marketing authorization for ANKTIVA across multiple indications and FDA acceptance of an sBLA with a PDUFA date of January 6, 2027. ImmunityBio also secured exclusive U.S. rights to Tokyo-172 BCG via an agreement with Japan BCG Laboratory. The company operates in the biotechnology industry, developing and commercializing immunotherapies for cancer.